Connexin 26 in psoriatic skin before and after two conventional therapeutic modalities: Methotrexate and PUVA

European Journal of Dermatology

Volumn 22, Issue 2, 2012, Pages 218-224

  Shaker, Olfat ^a   Abdel Halim, Mona ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Connexin 26; Gap junctions; Methotrexate; Psoriasis; PUVA

Indexed keywords

CONNEXIN 26; FOLIC ACID; METHOTREXATE; METHOXSALEN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALE; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS VULGARIS; PUVA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SKIN BIOPSY;

ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; CONNEXINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; PUVA THERAPY; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84859777731     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1649     Document Type: Article

References (51)

1. Breathnach AS. Aspects of epidermal ultrastructure. J Invest Dermatol 1975; 65(1):2.
2. Holbrook KA and Odland GF. The fine structure of developing human epidermis: light, scanning, and transmission electron microscopy of the periderm. J Invest Dermatol 1975; 65(1):16.
3. Salomon D, Saurat JH, and Meda P. Cell-to cell communication within intact human skin. J Clin Invest 1988; 82:248.
4. Brissette JL, Kumar NM, Gilula NB et al. Switch in gap junction protein expression is associated with selective changes in junctional permeability during keratinocyte differentiation. Proc Natl Acad Sci USA 1994; 91: 6453.
5. Dahl E, Winterhager E, Reu B et al. Expression of gap junction proteins connexin 31 and connexin 43 correlates with communication compartments in extraembryonic tissues and in the gastrulating mouse embryo respectively. J Cell sci 1996a; 109: 191.
6. Veenstra RD. Size and selectivity of gap junction channels formed from different connexins. J Bioenerget Biomembr 1996; 28: 327 (Cited from Luke et al., 1999).
7. Scott CA, Kelsell DP. Key functions for gap junctions in skin and hearing. Biochem J. 2011; 438(2):245-54.
8. Salomon D, Masgrau E, Vischer S et al. Topography of mammalian connexins in human skin. J Invest Dermatol 1994; 103:240.
9. Goliger J and Paul D. Expression of gap junction proteins Cx26, Cx31.1, Cx37 and Cx43 in developing and mature rat epidermis. Dev Dynamics 1994; 200: 1 (Cited from Luke et al., 1999).
10. Butterwecke A, Elfgang C, Willecke K et al. Differential expression of gap junction proteins connexin 45, 43, 40, 31 and 26 in mouse skin. Eur J Cell Biol 1994; 65: 152.
11. Dahl E, Manthey D, Chen Y et al. Molecular cloning and functional expression of mouse connexin 30, a gap junction gene highly expressed in brain and skin. J Biol Chem 1996b; 271: 17903.
12. Risek B, Klier FG, and Gilula NB. Developmental regulation and structural organization of connexins in epidermal gap junction proteins. Dev Biol 1994; 164: 183.
13. Goliger J and Paul D. Wounding alters epidermal connexin expression and gap junction mediated intercellular communication. Mol Biol Cell 1995; 6: 1491.
14. Scott CA, Tattersall D, O'Toole EA. Connexins in epidermal homeostasis and skin disease. Biochim Biophys Acta 2011; Sep 10 [Epub ahead of print].
15. Britz-Cunningham SH, Shah MM, Zuppan CW et al. Mutatons in the connexin 43 gap-junction gene in patients in patients with heart malformations and defects of laterality. N Engl J Med 1995; 332:1323.
16. Kelsell DP, Dunlop J, Stevens HP et al. Connexin 26 mutations in hereditary non syndromic sensorineural deafness. Nature 1997; 387:80.
17. Zelante L, Gasparini P, Estivil X et al. Connexin 26 mutations associated with the most common form of non-syndromic neurosensory autosomal recessive deafness (DFNB1) in Mediterraneans. Hum Mol Genet 1997; 6: 1605.
18. Schnichels M, Wörsdörfer P, Dobrowolski R et al. The connexin31 F137L mutant mouse as a model for the human skin disease erythrokeratodermia variabilis (EKV). Hum Mol Genet 2007; 16(10):1216.
19. Mazereeuw-Hautier J, Bitoun E, Chevrant-Breton J et al. Keratitisichthyosis-deafness syndrome: disease expression and spectrum of connexin 26 (GJB2) mutations in 14 patients. Br J Dermatol 2007; 156(5):1015.
20. Akiyama M, Sakai K, Arita K et al. A novel GJB2 mutation p. Asn54His in a patient with palmoplantar keratoderma, sensorineural hearing loss and knuckle pads. J Invest Dermatol 2007; 127(6): 1540.
21. Bondeson ML, Nyström AM, Gunnarsson U et al. Connexin 26 (GJB2) mutations in two Swedish patients with atypical Vohwinkel (mutilating keratoderma plus deafness) and KID syndrome both extensively treated with acitretin. Acta Derm Venereol 2006; 86(6):503.
22. Kelly SC, Ratajczak P, Keller M et al. A novel GJA 1 mutation in oculo-dento-digital dysplasia with curly hair and hyperkeratosis. Eur J Dermatol 2006; 16(3):241.
23. rd edition, 1998, Marcel Dekker Inc., New York, P. 315.
24. Bata Cosorgo Z, Hammerberg C, Voorhees, JJ et al. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol 1995; 105:89.
25. McKay IA and Leigh IM. Altered keratinocyte growth and differentiation in psoriasis. Clin Dermatol 1995; 13(2): 105.
26. Ruckert R, Assadullah K, Seifert M et al. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis. J Immunol 2000; 165: 2240.
27. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54: 567.
28. Kohn A, Ruland V, Patsinakidis N et al. Use of methotrexate in patients with psoriasis. Clin Exp Rheumatol 2010; 28 (5 S 61): S138-44.
29. Coven TR, Walters IB, Cardinale I et al. PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis. Photodermatol Photoimmunol Photomed 2009; Q1: 22-7.
30. Caputo R, innocenti M, Gasparini G et al. Plasma membranes in psoriatic cells. A freeze-fracture study. J Invest Dermatol 1978; 71:245.
31. Cavicchini S, Brezzi A, Gasparini G et al. Skin structure after calcipotriol treatment: a transmission electron microscopic and freeze fracture study on psoriatic patients. Acta Derm Venereol 1996; 76:186.
32. Rivas M, Jarvis E, Morisaki S et al. Identification of aberrantly regulated genes in diseased skin during cDNA differential display technique. J Invest Dermatol 1997; 108: 188.
33. Labarthe MP, Bosco D, Saurat JH et al. Upregulation of connexin 26 between keratinocytes of psoriatic lesions. J Invest Dermatol 1998; 111: 72.
34. Lucke T, Choudhry R, Thom T et al. Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis, vaginal epithelium and buccal epithelium. J Invest Dermatol 1999; 112: 354.
35. Marks R, Barton SP, Shuttleworth D et al. Assesment of disease progress in psoriasis. Arch Dermatol 1989; 125:235.
36. Shaker OG, Moustafa W, Essmat S et al. Role of IL-12 in Pathogenesis of Psoriasis. Clin. Biochem 2006;39 (2): 119-125.
37. nd edition, McGrawHill.
38. Hivnor C, Williams N, Singh F et al. Gene expression profiling of porokeratosis demonstrates similarities with psoriasis. J Cut Pathol 2004; 31(10): 657.
39. Pepper MS, Spray DC, Chanson M et al. Junctional communication is induced in migrating capillary endothelial cells. J Cell Biol 1989; 109 (6 Pt 1): 3027.
40. Lowenstein WR and Rose B. The cell-cell channel in the control of growth. Semin Cell Biol 1992, 3: 59.
41. Goodenough DA, Goliger JA and Paul DL. Connexins, connexons, and intercellular communication. Annu Rev Biochem 1996; 65:475.
42. Wilgenbus KK, Kirkpatrick CJ, Knuechel R et al. Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues. Int J Cancer 1992; 19;51(4):522.
43. Budunova IV, Carbajal S and Slaga TJ. The expression of gap junctional proteins during different stages of mouse skin carcinogenesis. Carcinogenesis 1995; 16(11):2717.
44. Mesnil M, Piccoli C and Yamasaki H. A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells. Cancer Res 1997; 57(14):2929.
45. Frank DK, Szymkowiak B and Hughes CA. Connexin expression and gap junctional intercellular communication in human squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 2006; 135(5):736.
46. Tanaka M and Grossman HB. connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. Oncol Rep 2004; 11(2): 537.
47. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997; 23(4):739.
48. Schwartz PM, Barnett SK, Atillasoy ES et al. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci USA 1992; 89(2):594.
49. Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med 2007; 357(7):682.
50. Provost N, Moreau M, Leturque A et al. Ultraviolet A radiation transiently disrupts gap junctional communication in human keratinocytes. Am J Physiol Cell Physiol 2003; 284(1): 51.
51. Bellei B, Mastrofrancesco A, Briganti S et al. Ultraviolet A induced modulation of gap junctional intercellular communication by P38 MAPK activation in human keratinocytes. Exp Dermatol 2008; 17(2):115.